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ABSTRACT
The  Coronavirus  disease  2019  (COVID-19)  is  caused  by  severe  acute  respiratory  syndrome
Coronavirus-2 (SARS CoV-2) infection attacking mainly on the immune system of a body. It is a
potentially fatal disease that is of public health and economy concern globally.  In December 2019,
COVID-19 outbreak occurred in Wuhan city, Hubei Province, China furthermore spread worldwide.
Research is underway in many countries to develop effective vaccines and drugs for the COVID-19.
In  Ayurveda,  Acharya  Charaka  explained  the  concept  of  an  epidemic  condition  in
Janapadodhwansa Adhayay  and combating of these diseases is to be done by  Panchakarma  (five
procedures of purification), Rasayana Chikitsa (immune-modulators therapy) and  Sadvritta (good
conduct).  Rasayan  dravyas (immunomodulator  drugs)  of  Ayurveda  can  be  used  for  health
promotion,  immune-modulation,  prevention  and  reduce  disease  burden from  COVID-19.  Drugs
such  as  Ashwagandha  (Withania  somnifera  (L.)  Dunal),  Guduchi  (Tinospora  cordifolia  (Willd.)
Miers),  Amalaki  (Phyllanthus  emblica L.),  Mulethi  (Glycyrrhiza  glabra  L.),  Shatavari (Asparagus
racemosus  Willd.),  Chireta (Andrographis  paniculata  (Burm.f.)  Nees),  Tulsi (Ocimum sanctum L.)
Punarnava  (Boerhaavia  diffusa L.) and Pippali  (Piper  longum L.)  For  symptom  management  of
COVID-19 like illness Agastya Haritaki,  Anutaila,  AYUSH–64 can be used. Scientific  research  on
these drugs may reveal the new approach for the prevention and management of COVID-19. The
main aim of this article is to review research which has already conducted and currently being
carried  out  on  the  herbal  plant  for  their  immunomodulation  property  which  have  a  possible
application in the prevention and treatment of COVID-19.
Introduction
From  the  beginning  of  the  21st  century,  three
coronaviruses  have  caused  grievous  outbreaks  of
respiratory  origin  in  human  beings.  Severe  acute
respiratory  syndrome  coronavirus  (SARS-CoV)  in
2002,  Middle-East  respiratory  syndrome
coronavirus  (MERS-CoV)  in  2012  and  at  present
COVID-19 is the third coronavirus pandemic (1).  In
December 2019 this RNA virus first reported in the
Wuhan  City,  Hubei  province  in  China  and  within
three  month  spread  to  nearly  72  countries  and
presently  reported  to  occur  in  188  countries  and
territories around the  world.  The  World  Health
Organization  (WHO)  declared  this  disease  as
pandemic  on  11  March  2020  (2).  In  a  very  short
period  COVID-19  has  caused  destabilizing  health
systems  and  economy around  the  world.  The  first
case  of  COVID-19  in  India  was  a  student  who
returned  from Wuhan,  China  on  January  30,  2020
(3). On  March  31,  2020,  Ministry  of  AYUSH  has
issued an advisory  note  on a variety of  immunity-
enhancing  steps,  supported  by  literature  of
Ayurveda,  scientific  publications  and  time  tested
approaches  to  resist  SARS-CoV-2  infection  by
enhancing the  immune response of the body (4). For
any  circumstances  prevention  from  diseases  is
better  than  cure  so  modulation  of  immune
responses by any measures may become beneficial
in reducing disease aggravation and mortality rate.
Now,  India  has  a  chance  proving  its  traditional
system  of  medicine  by  developing  evidence-based
prophylactic  and  curative  strategies  based  on
Ayurveda. 
The concept of pandemic disease is mentioned
by  Acharya  Charaka  in  Janapadodhwansa  Chapter
3rd in  Vimana  sthana.  Acharya  Charaka  explained
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that  Vayu (air), Jala (water), Desh (soil & area) and
Kala  (time) are four responsible  factors for group
infection in the community and further described
the whole concept of managing pandemic situation
(5). For any epidemic condition Panchakarma (five
procedures  of  purification),  Rasayana  Chikitsa
(immune-modulators therapy) and  Sadvritta (good
conduct)  are  leading  treatments  in  Ayurveda (5).
Among  these the  foremost  treatment  is  the
Rasayana  Chikitsa.  There  are  several  compounds
and  herbs  having  the  Rasayana effect.  Rasayana
drugs  enriches  the  basic  Dhatu  i.e.  Rasa which
further  resulted  in  Sapta  Dhatus of  optimum
quality and hence, body, soul and mind gets their
nourishment.  Rasayana dravyas is  mentioned  for
groups  of  important  drugs  that  supposed  to
improve  defence  mechanism  and  enhance
longevity (6).  Rasayana may be used in two ways,
either  as  a  prophylactic  medicine  or  as  a
preventive measure in healthy people (7).  Human
immune system is complex and there lies a delicate
balance  between  health  and  disease.  Any
substance,  synthetic  or  biological,  which  can
enhance, suppress or modulate the immune system
is  called  an  immunomodulator  drugs.  Till  date
many of the Rasayana dravyas are known for their
immunomodulatory  effects  via  modulation  of
cytokine  secretion,  histamine  release,
immunoglobulin  secretion,  lymphocyte  secretions
and  phagocytosis  and  so  on  (8).  Therefore,
Rasayana dravyas such as Ashwagandha (Withania
somnifera  (L.)  Dunal),  Guduchi  (Tinospora
cordifolia  (Willd.)  Miers),  Amalaki  (Phyllanthus
emblica L.),  Mulethi  (Glycyrrhiza  glabra  L.),
Shatavari (Asparagus  racemosus  Willd.),  Chireta
(Andrographis  paniculata  (Burm.f.)  Nees),  Tulsi
(Ocimum  sanctum L.) Punarnava  (Boerhaavia
diffusa L.) Pippali  (Piper  longum L.)  and  other
Ayurvedic  measures  like  Swarna  prashana  for
children  can  be  potential  drugs  for  providing
preventive,  supportive  and  rehabilitative  care  in
the treatment of COVID-19 patients by modulating
the immune system.
In  this  review,  the  concept  of  epidemic
diseases  and  Rasayana  in  Ayurveda,  a  brief
overview of COVID-19, mechanism of action of the
SARS-CoV-2  infection  in  the  human  host  cell  and
the potential use of certain Ayurvedic herbs for the
effective  treatment  of  COVID-19  has  been
discussed.  Through  this  review,  we  suggest  that
Ayuvedic Rasayan  dravyas (immuno  modulatory
drugs)  may be a beneficial  step to combat viruses
like  the  SARS-CoV-2  due  to  its  antiviral  and
immunomodulatory properties.
Materials and Methods
For  information  on  SARS-CoV-2  and  COVID-19,
authors searched major scientific databases namely
Pubmed,  Science  Direct,  Google  Scholar,  Springer
and  Elsevier  for  the  most  recent  information
regarding  the  pandemic.  The  search  words  used
were  ‘SARS-CoV-2’,  ‘COVID-19’,  ‘Immunopathology’
and immunomodulatory  and antiviral  herbal  drug
for COVID-19, bioactive compounds’ along with the
names  of  drugs,  according  to  their  use.  Classical
textbooks  of  Ayurveda (Charaka  Samhita  and  The
Ayurvedic Pharmacopeia of India) are reviewed for
documenting  the  information  about
Janapadodhwansa and Rasayan dravyas. The articles
published  during  2002–2020  were  included  in  the
manuscript.
Results 
Concept  of  Epidemics  and  Immunomodulatory
drugs in Ayurveda:
An epidemic is a disease that affects a large number
of  populations  within  a  community  or  region  and
the  pandemic  is  an  epidemic that's  spread  over
multiple countries at  the same time. Knowledge of
microorganism and epidemics are described in the
classical  textbook  of  Ayurveda.  Acharya  Sushruta
describes  that  the  diseases  like  Kustha (skin
disease),  Jwara (fever),  Shosha  (tuberculosis)
Netrabhishyanda (conjunctivitis) are contagious and
consider as  Aupasargika rogas  (9). They are spread
through direct contact or contaminated objects of a
patient.  Acharya  Charaka  has  coined  the  term
Janapadodhwansa which means the destruction of a
population  living  in  an  area  that  same  as  the
epidemic condition. Janapadodhwansa occurs due to
vitiation  of  Vayu  (air),  Jala  (Water),  Desh  (soil  &
area) and  Kala  (Time).They are nothing but modes
by which infectious diseases spread from one place
to another. Combating of these diseases is to be done
by  Panchakarma,  Rasayana  Chikitsa (immune-
modulators  therapy)  and  Sadvritta  (good  conduct)
(5). Ayurveda also has a concept of Agantuja Vyadhi
(exogenous diseases) and the term  Agantuja Vyadhi
is  implied  for  all  diseases  which  may  be  due  to
external  trauma  or  organisms  such  as  parasites,
viruses, bacteria, fungi etc. (10) So COVID-19 can be
treated  as  Agantuja  Vyadhi as  this  is  a  viral
infection. Rasayana can be a drug, diet or even a life
style  and  conduct  which  improves  the  state  of
nourishment, increased immunity and youthfulness.
Ayurveda describes  Rasayana drugs  as  having
which  claimed  to  have  immunomodulatory  and
antiviral properties (11). 
A brief overview of COVID-19:
COVID-19  is  a  respiratory pandemic  caused by
severe  acute  respiratory  syndrome  Coronavirus-2
(SARS-CoV-2).  SARS-CoV-2  has  96.2% structural
similarity with bat coronavirus and 79.5% similarity
with severe acute respiratory syndrome coronavirus
(SARS-CoV)  (12).  Coronaviruses  have  a  single
stranded  RNA  genome  covered  by  an  enveloped
structure (13). Size ranges of Coronaviruses are 26.2
-  31.7  kilobases  (kb)  and  50-200  nanometres  in
diameter  which is the largest for any RNA viruses.
The SARS-CoV-2 spike protein directly binds with the
host  cell  surface  ACE2  receptor  facilitating  virus
entry  and  replication.  SARS-CoV-2  uses  ACE2  as  a
cellular  entry  receptor  and  has 10–20  times  more
affinity as compared to SARS-CoV, leading to more
chances  of  human-to-human  transmission  (14). A
key question is why the lungs the most  susceptible
target organ. One reason is huge surface area, which
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makes  the  lungs  highly  susceptible  to  inhaled
viruses  and  another  that  83%  of  ACE2  cells  are
available  at  alveolar  epithelial  type II  cells  (AECII)
(15). Mortality rate of SARS-CoV-2 is lesser (average
3.4%) than SARS -CoV (9.6%) and MERS -CoV (35%)
(16). Common clinical features of COVID-19 include
fever (99%), dry cough (60%), myalgia (44%), fatigue
(70%)  and  breathlessness  still  in  advanced  stages
ARDS, kidney failure and even death can occur (17).
Ideal  laboratory  confirmation  of  a  suspected  case
includes nasopharyngeal and oropharyngeal swabs.
Nasopharyngeal  (NP)  swab  has  become  the
preferred  swab  as  it  is  tolerated  better  by  the
patient,  safe  to  operate.  SARS-CoV-2  RNA  was
detected  in  only  32%  of  OP  swabs,  which  was
significantly  lower  than  the  level  in  nasal  swabs
(63%)  (18).  At  present  confirmation  of  cases  of
COVID-19 is based on real-time reverse transcriptase
polymerase  chain  reactions  (RT-PCR)  with
confirmation by nucleic acid sequencing (19). COVID
-19  patients  can  discharge  from  hospital  if  they
show  two  negative  PCR  samples  from  the  throat
within 24 hrs (20).
SARS-CoV-2 and the immune system:
SARS-Co-V-2 has four structural proteins:  Spike (S),
Envelop (E), Membrane (M) and Nucleocapsid (N) in
which the first three are the viral envelop and RNA
genome is packaged by the nucleocapsid (N) protein
(13). For replication Coronavirus needs a host in the
form  of  a  living  cell.  SARS-CoV-2  mainly  alters
immune  regulatory  mechanism  and  damage
immune homeostasis (21). The immune response of
SARS-CoV-2 infection occurs in two phases:
Defence phase
When  Aerosolized  uptake  of  SARS-CoV-2  enters  in
lungs  which  leads  to  infection of  ACE2 expressing
target cells such as alveolar type 2 cells. This phase
generates  antibody-secreting  cells,  helper  T-cells
and  activated  CD4,  CD8  T-cells  that  bind  to  SARS-
CoV-2.  The  innate  immune  response  against  viral
infection  relies  on the  interferon (IFN)  type  I  and
control replication of the virus. SARS-CoV and SARS-
CoV-2  share  the  same  cell  receptor  in  the  human
entry  as  angiotensin-converting  enzyme  2  (ACE2)
but  MERS-CoV  uses  another  specific  receptor
dipeptidyl peptidase and amino peptidase N (22).
Damage phase
Lead  to  the  uncontrolled  release  of  cytokine  that
causing  cytokine  release  syndrome(CRS),  or
‘cytokine  storm’  characterized  by  increased
Interleukin 2 (IL-2), Interleukin 7 (IL-7), IFN-gamma,
tumor  necrosis  factor (TNF)-alpha4  etc.  Cytokine
release  syndrome  (CRS)  damages  tissues  of  the
lungs, kidney and heart that is likely lead to severe
complication  like  acute  respiratory  distress
syndrome  (ARDS),  respiratory  failure  and  death.
Cytokine  storm  and  lymphopenia  may  have  a
significant  role  in  the  pathogenesis  of  SARS-CoV-2
infection  (23).  TH1/TH2  cytokine levels  as  an
indicator  of  disease  progression in  human and  its
Restoration  establish  immune  homeostasis  (24).
Cytokines are the hormonal messengers responsible
for  immune  response  and  are  further  subdivided
into  Th1 and  Th2 which  varies  according  to  age.
Besides  the  immune  system,  another  important
system involve with COVID-19 is the nervous system
and  develop  neurological  symptoms,  including
headache,  disturbed consciousness and paresthesia
(25).
A  Possible  approach  to  the  prevention  and
management of COVID-19 through Ayurveda:
At present,  there are no specific  antiviral  drugs or
vaccines  verified  to  be  effective  against  COVID-19;
hence the stress is being laid mainly on preventive
measures  and  symptomatic  treatment  (26).  In  the
twenty one century the applications of herbal drugs
to maintain health and prevention from diseases are
gaining  immense  attention  around  the  world.
According  to  WHO  approximately  4  billion  people
(80%)  of  the  world  currently  depends  on  herbal
medicine  for  some  aspect  of  primary  health  care
(27).  In Ayurveda, Rasayana dravyas are known for
their  immunomodulation  and  rejuvenation
properties,  which  may  be  important  in  the
prevention and management of COVID-19. Clinically,
immunomodulatory  drugs  can  be  classified  into
Immunoadjuvant (enhancement of vaccine efficacy),
Immunostimulants (enhancements  of  body’s
immunity  through  innate  as  well  as  adaptive
immune  responses)  and  Immunosuppressants
(suppress  the  immune  system  in  organ  transplant
and  autoimmune  diseases)  (28).  Numerous
Rasayana drugs  demonstrated  the
immunomodulatory  effects  in  vitro  and  clinical
studies  such as  Ashwagandha  (Withania somnifera
(L.)  Dunal),  Guduchi  (Tinospora  cordifolia  (Willd.)
Miers), Amalaki (Phyllanthus emblica L.) etc. 
Ashwagandha (Withania somnifera (L.) Dunal) 
Ashwagandha known as Indian winter cherry and
Indian ginseng is one of the most important herbs
in Ayurveda and used for the immunomodulation,
combating infectious agents, management of stress
and  improves  good  physical  and  mental  health.
Ashwagandha  enhances  nitric  oxide synthetase
activity  of  the  macrophages,  which  help  in
improving  immune  cells.  Withania  somnifera
glycoprotein  (WSG)  is  a  potent  source  of
antimicrobial  activity  (29).  Ashwagandha  helps  to
restore  immune  homeostasis  by  providing
immune-suppression  or  immune  stimulation
effects.  Ashwangandha provides  anti-viral
immunity  by  increasing  Interferon gamma (IFN-
gamma responses) and anti-inflammatory activities
by  decreasing  the  quantity  of  Interleukin -1,
Interleukin -6 and Tumor necrosis factor which are
the  main  factors  related  to  COVID-19.
Ashwangandha  may  be  an  effective  agent  in  the
management of COVID-19 infection by modulation
of host Th-1/Th-2 immunity.  Ashwagandha extract
gives  competent  protective  immune  responses
when  added  with  DPT  (Diphtheria,  Pertusis,
Tetanus)  vaccine  against  fatal  outcome  of
diphtheria and pertussis toxins (30). Ashwagandha
helps  enhancement  of  immunogenicity  and
constructive  effect  on  symptoms  in  conjunction
with  anti-tuberculosis  drugs  used  as  a  directly
observed treatment, short-course (DOTS) (31).
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Guduchi (Tinospora cordifolia (Willd.) Miers)
Guduchi is one of the best  Rasayana and known as
“Amrita”  means  rejuvenate  dead  cells  and  have
immuno-modulatory and enhances innate immunity
against COVID-19 infections. Tinosporin, diterpenoid
has very effective anti-viral property especially for
the  treatment  of  retroviruses  and  other  viral
diseases  (32).  Aqueous  extracts T.  cordifolia has
influenced the cytokine production and activation of
immune  effector  cells  (33).  Guduchi  is  a  potent
hepato-protective  so  effective  in  preventing  in
hepatotoxicity.  It  enhances  the  level  of  vitamin  C
and thus functions as an antioxidant (34). Guduchi
stem  has  immunomodulatory  protein  which
increases  the  number  of  macrophages  and  its
phagocytic activity (35). Sanshamani Vati (also called
Guduchi ghana vati) which contains aqueous extract
of T. cordifolia can be adviced as 500 mg twice a day,
15  days  with  warm  water  as  a  preventive  and
prophylactic drug for COVID-19 (36).
Amalaki (Phyllanthus emblica L.)
Amalaki is a rich source of vitamin C (Ascorbic acid)
(37). Acharya Charaka has described that Amalaki is
the  best  rejuvenating  herb  (38)  and  useful  in
relieving  cough  and  skin  diseases  (39).  Amalaki
improves both cell mediated and humoral immune
response. It enhances IL-2, gamma –IFN and natural
killer  (NK)  cell  activity.  Amalaki is  a  well-known
drug  for  its  anti-oxidant,  detoxification  and
antiaging  activity  (40).  P.  emblica has  an
antibacterial  effect  on  Gram-negative  and  Gram-
positive organisms due to the presence of flavonoids
component.  Antimicrobial  activity  of  flavonoids  is
probably  due  to  the  ability  to  form complex  with
extracellular and soluble proteins, or with bacterial
cell walls which disrupts the microbial membranes
(41).  Pulmonary  antioxidant  defences  are  widely
distributed in lungs and include both enzymatic and
non-enzymatic systems. The primary non-enzymatic
antioxidants  are  membrane-bound  vitamin  C  and
vitamin E. Amalaki is the richest source of vitamin C
(42).
Mulethi (Glycyrrhiza glabra L.)
The  major  photo  components  reported  in  Mulethi
(Yashtimadhu)  is  glycyrrhizin  which  is  promising
candidates  in  inhibiting  replication  of  the  SARS-
associated  virus  (43).  Mulethi  (Yashtimadhu)
improves the resistance against the herpes simplex
virus  type  1  (HSV-1)  by  Type  I  and  II  interferons
(IFN) and Th2 cytokines secretion (44).  It  has anti-
viral  activity  against  Human  immunodeficiency
virus (HIV),  potent  immunomodulatory  and
antioxidant activity (45). 
Shatavari (Asparagus racemosus Willd.)
Shatavari  is  an  important  Ayurvedic  rejuvenating
tonic  for  the  female,  as  Ashwagandha  (Withania
somnifera)  for  the  male.  Shatavari has  a  potent
immunomodulatory  property  by  altering  the
function  of  macrophages  (46).  It  has
immunoadjuvant  potential  with  Diphtheria,
Tetanus,  Pertussis  (DPT)  vaccine by significant  up-
regulation of Th-1, Th-2 and cytokines and immuno-
stimulation property by significant increase of CD4/
CD8 along with T cell activation (47).
Kalmegha  (Andrographis  paniculata  (Burm.  f.)
Nees)
Kalmegha  is  an  important  Ayurvedic  drug  which
has the capacity to treat viral respiratory infections
and enhance the immune response.  It has viricidal
activity against Herpes simplex virus 1 (HSV-1) and
HIV  by  a  significant  rise  in  the  mean  CD4+
lymphocyte  level  (48).  Andrographolides,  the  main
ingredient of A. paniculata enhance immune system
such as the production of white blood cells, release
of interferon and activity of the lymph system. The
lymph  carries  away  the  by-products  of  cellular
metabolism  and  acts  as  a  shuttle  for  invading
bacteria  and  viruses.  The  wide  tissue  and  organ
distribution  and  the  immune-stimulating  and
regulatory  actions  of  Kalmegha make  it  an  ideal
candidate in the prevention and treatment of many
diseases and conditions (49).
Tulsi (Ocimum sanctum L.)
Tulsi is regarded as mother medicine of nature and
it  shortens the course of all  illness.  Tulsi  has anti-
bacterial,  anti-viral  and anti-fungal  activity  (50).  A
decoction of the leaves of Tulsi  is beneficial for the
treatment  of  respiratory  disorders  (bronchitis,
asthma, influenza, cough and cold) (51). Flavonoids
present  in  the  extracts  of  Tulsi  leaves  have  been
found to be responsible for the immunomodulatory
properties  by  the  increased  level  of  IL-4,  natural
killer  cells  and helper  cells  (52).  The essential  oils
like  Eugenol  of  Tulsi  leaves  produce  anti-viral
activity against different viruses e.g. polio virus type
3,  herpes  virus  (HSV),  hepatitis  B  virus  etc.  (53)
Ethanolic extract of Tulsi plant leaves in a range of
22.5 mg/ml concentration inhibit replication of polio
type 3 virus. The extracted components of Tulsi like
linalool and ursolic acid has shown broad- spectrum
antiviral activity against DNA viruses like RNA virus
and adenoviruses (54).
Punarnava (Boerhaavia diffusa L.)
Punarnava has immunomodulatory effects due to its
immunosuppressive  and  immunostimulatory
activity  (55).  Administration  of  Punarnava
significantly  reduced  the  elevated  levels  of  pro-
inflammatory cytokines such as TNF-alpha, IL-1beta,
and  IL-6  in  mice.  These  results  indicate  the
immunomodulatory  activity  of  Punarnava  (56).
Extracts  of  B. diffusa roots  have anti-inflammatory
activity  by  inhibiting  natural  killer  (NK)  cell,
cytotoxicity,  production  of  nitric  oxide in  human
and very high antiviral activity (57).
Pippali (Piper longum L.)
Pippali  Rasayana, a famous Ayurvedic preparation,
reported having significantly activated macrophages
in an experimental study on mice. Administration of
P.  longum extract  and  its  phytochemical  piperine
increased  the  total  WBC  count,  Bone  marrow
cellularity and α-esterase positive cells in mice (58).
Immunomodulatory  action  of  Pippali  fruits  (via
modulation  of  both  specific  and  non-specific
immune  response)  has  been  reported  by  using
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macrophage  migration  index  (MMI),  haem-
agglutination titre (HA) and phagocytic index (PI) in
mice.  The  effect  was  more  prominent  at  a  lower
dose (225 mg/kg) and was marginally reduced when
the  dose  was  increased  (59).  Pippali  Rasayana,  a
famous  Ayurvedic  preparation,  reported  to
activating  macrophages  significantly  in  mice,
infected  with  Giardia  lamblia  as  shown  by  an
increased MMI and phagocytic activity.
Swarna-prashana:
‘Suvarna-prashana’ (SP) is also a Rasayan mentioned
by  Acharya  Kashyap in  Kashyapa  Samhita,  Sutra
Sthana,  Lehadhyaya  (60)  but  the  use  of  Suvarna
(Gold) is generally mentioned by many Acharyas for
administration during the early infantile period for
improvement of  memory,  digestion and immunity.
Suvarna-prashana is  a  preventive  measure  which
acts probably  via  the  process  of
immunomodulation.  In  the  procedure  of  Suvarna-
prashana, gold is rubbed on a white stone with the
help  of  the  little  amount  of  water  and  is
administered along with honey and ghee.  In some
places,  Swarna Bhasma is administered to newborn
babies with honey and ghee and some other drugs
like  Vacha  (Acorus  calamus L.),  Brahmi  (Bacopa
monnieri (L.)  Wettst)  and  Shankhapushpi
(Convolvulus  pluricaulis Choisy)  etc.  (61)  Swarna-
prashana can  be  administered  in  all  children
because it acts at the level of nutrition, growth and
development,  physical  strength  and  immunity.  An
experimental  on  mice  showed  that  it  improves
nonspecific  immune  responses  and  stimulatory
effect  on  peritoneal  macrophages,  which  may  be
helpful to fight against infections (62).
Appropriate  exploration  of  herbal  drugs  is
urgently  needed  for  prophylactic  and  treatment
solutions to COVID-19.
Symptomatic treatment from Ayurveda:
AYUSH neither has claimed effective treatment for
Corona  virus  nor  any  specific  drug  to  combat  for
COVID-19.  Some  classical  formulations  such  as
Sudarshan Ghana vati and Sanshamani vati are used
as safer symptomatic measures for conditions such
as  coryza  and  fever.  AYUSH  recommended  some
Ayurvedic  drugs  for  symptoms  management  of
COVID-19 like illness described in (Table 1).
Ongoing clinical trials:
For  validation  of  Ayurvedic  formulation,  against
COVID-19,  the  AYUSH  Ministry  and  the  Council  of
Scientific and Industrial Research (CSIR) has started
collaborative  work  on  four  Ayush  formulations.
These formulations are Ashwagandha, Yashtimadhu
(Mulethi),  Guduchi  +  Pippali  and  AYUSH-64.  The
competitive  study  is  also  planned  between
Hydroxychloroquine and Ashwagandha for a high-
risk population (63).
Conclusion
Coronavirus  disease  2019  (COVID-19)  has  emerged
as  the  most  hazardous  pandemic  risk  throughout
the world since its outbreak during December 2019.
It has become a big challenge for the researchers to
find  a  solution  for  this  deadly  epidemic  because
SARS-CoV-2  has  a  high  rate  of  mutagenesis.  SARS-
CoV-2 mainly alters immune regulatory mechanism
and damage  immune homeostasis.  Viral  infections
induce oxidative stress and cause damage to airway
epithelial cells.  Cytokine release syndrome (CRS) or
‘cytokine  storm,  damages  tissues  of  the  lungs,
kidney  and  heart  that  in  future  lead  to  severe
complication  like  ARDS,  respiratory  failure,  shock
and potentially death.
Ayurveda recommends  prophylaxis  measures
for  respiratory  diseases  that  may  be  beneficial  in
COVID-19  prevention.  In  Ayurveda,  ‘Rasayan
dravyas’  are  described  which  concerned  with
nourishing  the  body,  boosting  immunity  and
modulators  of  the  immune  system.  Some  of  the
Rasayanas  are scientifically validated and found to
have  the  immunomodulatory  effect  like
Aswagandha  (Withania  somnifera  (L.)  Dunal),
Amalaki  (Phyllanthus  emblica L.),  Tulasi  (Ocimum
sanctum L.),  Guduchi  (Tinospora  cordifolia  (Willd.)
Miers),  Pippali  (Piper  longum L.)  etc.  Since  many
Indian  medicinal  plants  exhibit  antiviral,  anti-
inflammatory and antioxidant properties, it may be
favorable  to  consider  them  for  the  treatment  of
COVID-19. Standard clinical trials should be carried
out to scientifically prove its efficacy.
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Table 1. Ongoing clinical trials in Ayurveda for COVID-19
Drug Ingredients Dose Indication
Tab. AYUSH -64
Saptaparna stem bark (Alstonia scholaris (L.) R. Br.), Katuki roots 
(Picrorhiza kurroa Royle ex Benth.), Chirayata whole plant 
(Swertia chirata Buch.-Ham. ex Wall.) and Kuberaksha seed 
(Caesalpinia crista L.) (64)
2 tablets twice a day. Respiratory infections
Agastya Haritaki churna 
(powder)
Haritaki ( Terminalia chebula Retz.), Dashamoola, Pippali ( Piper 
longum L.) etc. (65)
5 grams twice a day with 
warm water.
Respiratory 
infections
Anuthaila (oil) Anutaila consists of a 27 ingredient likeSesame oil, Vidanga (Embelia ribes Burm.f) , Ajadugdha (goat 
milk) etc. (66)
2 drops in each nostril 
daily morning.
Respiratory 
infections
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